

Siemens, Novartis to develop assays

December 2020—Siemens Healthineers announced a master collaboration agreement with Novartis Pharma to design, develop, and commercialize diagnostic tests for therapeutic products across Novartis' therapeutic pipeline. The initial program will focus on developing a serum neurofilament light chain immunoassay for patients with multiple sclerosis and other neurological diseases.

The tests will run on Siemens Advia Centaur and Atellica immunoassay platforms.

[*Siemens Healthineers*](#), 888-826-9702